Fig. 2From: A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational studyPLT elevation according to the PLT level before lusutrombopag administrationPLT elevation according to the PLT level before lusutrombopag administrationWe examined whether there was a difference in the rate of PLT elevation depending on the pre-dose PLT level. There was no difference in the rate of PLT elevation between patients who met with a pre-dose PLT level of ≥ 50,000 PLT µL− 1 and those who met with a pre-dose PLT level of < 50,000 PLT µL− 1 (p = 0.4017)Back to article page